David Hung
Patrick Machado
- Medivation is developing MDV3100, a novel, oral anti-androgen drug candidate for prostate cancer. After a successful Phase 2 trial, Medivation advanced MDV3100 into a pivotal Phase 3 trial in September 2009.
- Aquilo assisted Medivation throughout the MDV3100 partnering process, helping the company evaluate the financial, strategic and corporate governance aspects of potential partnerships.
- The economic aspects of the deal with Astellas include:
- $110 million upfront payment
- up to $335 million of development milestones
- up to $320 million of commercial milestones 50/50 split of US profits
- tiered double-digit royalties on ex-US sales
|
